Skip to main content
. 2017 Apr 10;8(29):47154–47160. doi: 10.18632/oncotarget.17005

Figure 1.

Figure 1

(A) Median PFS is significantly improved for patients with RECIST responses (P-value for the trend =0.0004). (B) Median OS is significantly improved for patients with RECIST response (P-value for the trend =0.0005).